Roger Von Moos
Overview
Explore the profile of Roger Von Moos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
2699
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vener C, Lillini R, De Angelis R, Bonfarnuzzo S, Poirel H, Trama A, et al.
Eur J Cancer
. 2025 Mar;
220:115231.
PMID: 40056559
Background: EUROCARE, a European population-based cancer project, has shown geographical survival disparities for myeloid neoplasms (MN) suggesting healthcare inequalities. Total National Health Expenditure (TNHE) might influence population-based MN survival. We...
2.
El Saadany T, Lupatsch J, Mark M, Barbier M, Mehra T, Schwenkglenks M, et al.
Swiss Med Wkly
. 2025 Jan;
155():3777.
PMID: 39835711
Background And Objective: Because of the lack of effective targeted treatment options, docetaxel has long been the standard second-line therapy for patients with advanced non-small cell lung cancer, including the...
3.
Mehra T, Lupatsch J, Koessler T, Dedes K, Siebenhuner A, Von Moos R, et al.
PLoS One
. 2024 Dec;
19(12):e0315976.
PMID: 39666698
[This corrects the article DOI: 10.1371/journal.pone.0301271.].
4.
Bastian S, Joerger M, Holer L, Bartschi D, Guckenberger M, Jochum W, et al.
Clin Colorectal Cancer
. 2024 Nov;
24(1):82-88.e1.
PMID: 39537446
Background: The multi tyrosine kinase inhibitor regorafenib is active in metastatic colorectal cancer. Improvement in clinical outcome by adding regorafenib to long-course chemoradiotherapy (LcCRT) was investigated in molecularly undefined LARC....
5.
Mark M, Mora A, Winder T, Stathis A, Jakob A, Muller G, et al.
Bone Rep
. 2024 Aug;
22:101794.
PMID: 39139592
Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading...
6.
Jolidon V, Eicher M, Peytremann-Bridevaux I, Aebi S, Anchisi S, Bettini A, et al.
Cancer
. 2024 Aug;
130(24):4334-4346.
PMID: 39119752
Background: Patient experience surveys gather information on various aspects of care via numerous survey items. Identifying the most critical areas of patient experience to prioritize for quality care improvement can...
7.
Johnson K, Stoffel B, Schwitter M, Hayoz S, Mora A, Maranta A, et al.
Support Care Cancer
. 2024 Jul;
32(8):554.
PMID: 39066890
Purpose: Common side effects of taxane chemotherapy are nail toxicity and peripheral neuropathy (CIPN) causing severe impact on the quality of life. Different methods of cryotherapy to prevent these side...
8.
Mehra T, Lupatsch J, Kossler T, Dedes K, Siebenhuner A, Von Moos R, et al.
PLoS One
. 2024 Apr;
19(4):e0301271.
PMID: 38573891
Objective: To assess the cost-effectiveness and budget impact of olaparib as a maintenance therapy in platinum-responsive, metastatic pancreatic cancer patients harboring a germline BRCA1/2 mutation, using the Swiss context as...
9.
Mark M, Froesch P, Gysel K, Rothschild S, Addeo A, Ackermann C, et al.
Eur J Cancer
. 2024 Feb;
200:113600.
PMID: 38330766
Introduction: The safety and efficacy of first-line durvalumab in PS2 patients with advanced NSCLC is unknown. Here, we present the primary analysis of first-line durvalumab in PS2 patients, unsuitable for...
10.
de Joode K, Mora A, van Schaik R, Zippelius A, van der Veldt A, Gerard C, et al.
J Immunother
. 2024 Feb;
47(5):190-194.
PMID: 38318726
Single nucleotide polymorphisms (SNPs) in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene, an inhibitor of T-cell priming, are associated with auto and alloimmunity. Studies implied a role for these SNPs...